Your browser doesn't support javascript.
loading
Inhibition of aldehyde dehydrogenase by furazolidone nanoemulsion to decrease cisplatin resistance in lung cancer cells.
Darooee, Mina; Akbari, Vajihe; Taheri, Azade.
Afiliación
  • Darooee M; Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Akbari V; Department of Pharmaceutical Biotechnology & Isfahan Pharmaceutical Research Center, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Taheri A; Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Ther Deliv ; 12(8): 611-625, 2021 08.
Article en En | MEDLINE | ID: mdl-34286601
Aim: The overexpression of aldehyde dehydrogenase (ALDH) in cancer cells contributes to therapeutic resistance. Furazolidone (FUR) is a strong ALDH inhibitor. Methods: FUR nanoemulsion (NE) was formulated and tested for ALDH inhibitory activity in comparison with free FUR. The cytotoxic potential of cisplatin was evaluated in combination with free FUR and FUR NE. Results: The optimized FUR NE showed droplet size of 167.9 ± 3.1 nm and drug content of 84.2 ± 2.3%. FUR NE inhibited 99.75 ± 2.1% of ALDH activity while 25.0 ± 4.6% was inhibited by free FUR. FUR NE increased the sensitivity to cisplatin in A549 cells by more than tenfold by its ALDH inhibitory effects. Conclusion: This finding can be a promising approach to improve cancer survival in ALDH-positive drug-resistant cancers.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cisplatino / Aldehído Deshidrogenasa / Furazolidona / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Ther Deliv Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cisplatino / Aldehído Deshidrogenasa / Furazolidona / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Ther Deliv Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido